Evidence map›Paper›PMID 32917725›Full record

ArticleThe Journal of biological chemistry2020

Glycerophosphodiesterase 3 (GDE3) is a lysophosphatidylinositol-specific ectophospholipase C acting as an endocannabinoid signaling switch.

Fabienne Briand-Mésange, Véronique Pons, Sophie Allart, Julien Masquelier, Gaëtan Chicanne, Nicolas Beton, Bernard Payrastre, Giulio G Muccioli, Jérôme Ausseil, Jean-Luc Davignon and 2 more

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Metabolic Consequences of Gestational Cannabinoid Exposure.International journal of molecular sciences · 2021
    Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Fabienne Briand-MésangeCenter for Physiopathology of Toulouse Purpan, University of Toulouse, Toulouse, France; National Center for Scientific Research, Toulouse, France; National Institute of Health and Medical Research, Paul Sabatier University, Toulouse, France.
Véronique PonsInstitute of Metabolic and Cardiovascular Diseases, Toulouse, France; National Institute of Health and Medical Research, Paul Sabatier University, Toulouse, France.
Sophie AllartCenter for Physiopathology of Toulouse Purpan, University of Toulouse, Toulouse, France; National Center for Scientific Research, Toulouse, France; National Institute of Health and Medical Research, Paul Sabatier University, Toulouse, France.
Julien MasquelierBioanalysis and Pharmacology of Bioactive Lipids Research Group, Louvain Drug Research Institute, Catholic University of Louvain, Brussels, Belgium.
Gaëtan ChicanneInstitute of Metabolic and Cardiovascular Diseases, Toulouse, France; National Institute of Health and Medical Research, Paul Sabatier University, Toulouse, France.
Nicolas BetonCenter for Physiopathology of Toulouse Purpan, University of Toulouse, Toulouse, France; National Center for Scientific Research, Toulouse, France; National Institute of Health and Medical Research, Paul Sabatier University, Toulouse, France.
Bernard PayrastreInstitute of Metabolic and Cardiovascular Diseases, Toulouse, France; National Institute of Health and Medical Research, Paul Sabatier University, Toulouse, France.
Giulio G MuccioliBioanalysis and Pharmacology of Bioactive Lipids Research Group, Louvain Drug Research Institute, Catholic University of Louvain, Brussels, Belgium.
Jérôme AusseilCenter for Physiopathology of Toulouse Purpan, University of Toulouse, Toulouse, France; National Center for Scientific Research, Toulouse, France; National Institute of Health and Medical Research, Paul Sabatier University, Toulouse, France.
Jean-Luc DavignonCenter for Physiopathology of Toulouse Purpan, University of Toulouse, Toulouse, France; National Center for Scientific Research, Toulouse, France; National Institute of Health and Medical Research, Paul Sabatier University, Toulouse, France.
Jean-Pierre SallesCenter for Physiopathology of Toulouse Purpan, University of Toulouse, Toulouse, France; National Center for Scientific Research, Toulouse, France; National Institute of Health and Medical Research, Paul Sabatier University, Toulouse, France.
Hugues ChapCenter for Physiopathology of Toulouse Purpan, University of Toulouse, Toulouse, France; National Center for Scientific Research, Toulouse, France; National Institute of Health and Medical Research, Paul Sabatier University, Toulouse, France. Electronic address: hugues.chap@inserm.fr.
Université Toulouse III - Paul Sabatier · FRUCLouvain · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Endocannabinoid signaling plays a regulatory role in various (neuro)biological functions. 2-arachidonoylglycerol (2-AG) is the most abundant endocannabinoid, and although its canonical biosynthetic pathway involving phosphoinositide-specific phospholipase C and diacylglycerol lipase α is known, alternative pathways remain unsettled. Here, we characterize a noncanonical pathway implicating glycerophosphodiesterase 3 (GDE3, from

Indexed as

Signal TransductionAmino Acid SequenceAnimalsArachidonic AcidsEndocannabinoidsFemaleGlyceridesHEK293 CellsHumansHydrolysisInositol PhosphatesLysophospholipidsMaleMiceMice, Inbred C57BLMice, KnockoutArachidonic AcidsCNR2 protein, humanEndocannabinoidsGlyceridesglycerophosphodiester phosphodiesteraseglyceryl 2-arachidonateGPR55 protein, humaninositol 1-phosphateInositol PhosphateslysophosphatidylinositolLysophospholipidsMonoglyceridesPhosphoric Diester HydrolasesReceptor, Cannabinoid, CB2Receptors, Cannabinoid2-arachidonoylglycerolCB1CB1/CB2CB2endocannabinoidGDPD2)glycerophosphodiesterase 3 (GDE3GPR55G-protein–coupled receptor (GPCR)lysophosphatidylinositollysophospholipidmonoacylglycerolphospholipase C

Identifiers

PMID32917725
PMCPMC7667972
OpenAlexW3086797253

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.